Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Ebola vaccine okayed in monkey trials: study

08 September 2014, 06:56

Paris - A novel vaccine temporarily shielded lab monkeys from Ebola, and a booster jab provided lasting protection, according to a study Sunday that endorsed approval for tests on humans.

A single shot of the vaccine, based on a cold virus that affects chimps, gave macaques "complete short-term and partial long-term protection" from the deadly virus, researchers reported in the journal Nature Medicine.

Animals that received a booster shot developed "durable" immunity.

Also Read: Ebola: Red Cross trains personnel, journalists on Ebola prevention

The US National Institute of Allergy and Infectious Diseases (NIAID) announced on August 28 that human testing would start in early September following the promising results in monkeys.

The results of these early trials are expected by year's end.

If approved, "this vaccine will be beneficial for populations at acute risk during natural outbreaks or others with a potential risk of occupational exposure," said the study's authors.

They claimed to be the first to demonstrate a vaccine with "durable protection" against Zaire ebolavirus, which has killed 1,841 of the 3,685 people infected in Guinea, Liberia and Sierra Leone, according to World Health Organisation (WHO) numbers.

Nigeria has had another 21 cases and seven deaths from the haemorrhagic fever against which no licenced vaccine or treatment exists.

Nancy Sullivan of NIAID's Vaccine Research Center led a team that developed the vaccine based on a type of chimpanzee virus dubbed ChAd3.

The virus is used as a carrier, or vector, to deliver snippets of Ebola DNA into human cells.

The genetic material is non-infectious, but stimulate the cells of the vaccine recipient to recognise Ebola and mount an immune response against it.

The carrier virus is from the adenovirus family, which can cause colds, diarrhoea or bladder infection, and does not replicate in the vaccine recipient.

The research team said they had opted for a chimp adenovirus rather than a human one because many people have been exposed and developed immunity to the human versions, meaning their immune systems would be primed to neutralise them.

For the study, the team gave different doses of the ChAd3 vaccine to a small group of monkeys, and then a dose of Ebola that would be lethal in non-immune individuals.

Also Read: Protalix shares jump on report of possible Ebola drug technology

Some of the macaques also received a booster vaccine.

Four monkeys that received a single shot were immune when exposed to Ebola five weeks later, the researchers reported.

The protective effects waned over time, and by 10 months only two of the monkeys were still protected.

All four monkeys that were given the initial shot and a booster eight weeks later were fully protected against infection ten months after the initial injection, said the team.

The booster shot used a different vector, a pox virus, to deliver the Ebola genetic material.

The early trials in humans are the first phase in a three-step vetting process.

They will be carried out among healthy adults not infected with the Ebola virus to determine if it is safe and induces an adequate immune response.



Read News24’s Comments Policy

Comment on this story
1 comment
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...